Mersana Therapeutics, Inc.
MRSN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $40 | $37 | $27 | $0 |
| % Growth | 9.9% | 38.7% | 61,716.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $40 | $37 | $27 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $73 | $148 | $173 | $132 |
| G&A Expenses | $41 | $60 | $57 | $37 |
| SG&A Expenses | $41 | $60 | $57 | $37 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $114 | $208 | $230 | $169 |
| Operating Income | -$73 | -$171 | -$204 | -$169 |
| % Margin | -181.1% | -463.9% | -766.6% | -392,693% |
| Other Income/Exp. Net | $5 | -$1 | -$0 | -$1 |
| Pre-Tax Income | -$69 | -$172 | -$204 | -$170 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$69 | -$172 | -$204 | -$170 |
| % Margin | -170.9% | -465.8% | -768.3% | -395,488.4% |
| EPS | -14.12 | -36.96 | -54.51 | -60.24 |
| % Growth | 61.8% | 32.2% | 9.5% | – |
| EPS Diluted | -14.12 | -36.96 | -54.51 | -60.24 |
| Weighted Avg Shares Out | 5 | 5 | 4 | 3 |
| Weighted Avg Shares Out Dil | 5 | 5 | 4 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8 | $12 | $3 | $0 |
| Interest Expense | $4 | $4 | $3 | $1 |
| Depreciation & Amortization | $2 | $2 | $1 | $1 |
| EBITDA | -$63 | -$166 | -$200 | -$168 |
| % Margin | -156.2% | -450.6% | -752.3% | -390,553.5% |